Search
PF-04856884
go.drugbank.com/drugs/DB17550InvestigationalPF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. … [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Dosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalDosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South … Dosulepsin is a thio derivative of [DB00321] with a similar efficacy to that of [DB00321], and also exhibits anticholinergic, antihistamine and central sedative properties [L882].
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsAcetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703] … Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid[L1702] and it is the first monomeric ionic compound used as an X-ray contrast agent.
Categories: Compounds used in a research, industrial, or household settingAtracurium besylate
go.drugbank.com/drugs/DB00732ApprovedA non-depolarizing neuromuscular blocking agent with short duration of action.
Products: ATRACURIUM LABATEC IV SOLUTION FOR INJECTION 10MG/MLGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalThis drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830] … Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNimodipine
go.drugbank.com/drugs/DB00393ApprovedInvestigationalNimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. … Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: Nimotop IV 0.2mg/mlLomitapide
go.drugbank.com/drugs/DB08827Approved[A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … [A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A InhibitorsDiethyltoluamide
go.drugbank.com/drugs/DB11282ApprovedIt is widely used to repel biting pests such as mosquitoes and ticks. … And, despite concerns over excessive exposure to the chemical, appropriate usage of the chemical at the recommended dosages and routes of administration have generally proven to be safe - even when most
Categories: Compounds used in a research, industrial, or household settingPF-4191834
go.drugbank.com/drugs/DB11645InvestigationalPF-4191834 has been investigated for the basic science of Asthma.
PF-07799933
go.drugbank.com/drugs/DB17489InvestigationalPF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.